Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib 14/7 toxicity-adjusted dosing for metastatic renal cell cancer
ACTRN12616001639415Phase 2Not yet recruiting
- Sponsor
- Macquarie University
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in renal cell carcinoma (RCC), sponsored by Macquarie University. Planned start Dec 2016; status: not yet recruiting.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ACTRN12616001639415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001639415.